Navigation Links
Erlotinib effective and with fewer side-effects after first-line treatment
Date:2/26/2011

The targeted cancer drug erlotinib has comparable efficacy to chemotherapy, and is better tolerated, in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy, the results of a new phase III trial show.

Dr Tudor Ciuleanu from the Institute of Oncology Ion Chiricuta, Cluj-Napoca, Romania, reported this finding from the international TITAN study at the European Multidisciplinary Conference in Thoracic Oncology (EMCTO), 24-26 February 2011, Lugano, Switzerland.

"The TITAN study is the first trial to evaluate whether erlotinib has comparable efficacy to chemotherapy for non-small cell lung cancer patients in general," Dr Ciuleanu said.

The study included only patients whose disease had progressed under first-line chemotherapy. In the clinic, around 30-40% of patients with lung cancer will see no benefit from first-line therapy and their disease will rapidly progress.

"These patients have an extremely poor prognosis and few treatment options. An effective alternative to chemotherapy is therefore very important, since chemo-related side-effects can result in further physical deterioration in patients who are already very sick," Dr Ciuleanu said.

Historically, data have shown that erlotinib was more tolerable than chemotherapy, but many physicians had assumed that erlotinib would not be as effective in this difficult-to-treat patient population compared to chemotherapy.

The open-label study included 424 patients whose lung cancer had progressed rapidly after treatment with first-line chemotherapy. Of these, 203 were treated with erlotinib, and 221 received chemotherapy with either docetaxel or pemetrexed.

No difference in overall survival was seen between the two groups, the researchers reported. Nor was there any significant difference in progression-free survival time.

"TITAN is important because it confirms that erlotinib has comparable efficacy
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Oncogene AEG-1 strongly predicts response to erlotinib treatment in EGFR-mutant lung cancer
2. New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer
3. Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer
4. NYU nursing-dental team receives grant to assess effectiveness of A1C diabetes screening technique
5. Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management
6. Baker Institute conference to examine safety, effectiveness of US offshore drilling industry
7. Early tests find nanoshell therapy effective against brain cancer
8. Immersive data collection, peer networks among key elements of effective watershed councils
9. Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management
10. Marinomeds iota-carrageenan effective against H1N1
11. Estrogen alone is effective for reducing breast cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... the Red Queen in Lewis Carroll,s Through the ... and National University of Singapore improved a 35-year-old ... over decades to millions of years. , The ... competition, incorporates the "Red Queen Effect," an evolutionary ... 1970s, which suggests that organisms must constantly increase ...
(Date:7/30/2014)... tended her eggs until they hatched 4.5 years later, ... the open-access journal PLOS ONE by Bruce ... , Octopuses typically have a single reproductive period during ... of their fertilized eggs until they hatch. Shallow-water octopuses ... months, but little is known about the brooding of ...
(Date:7/30/2014)... The American Chemical Society (ACS) announced today that David ... ACS Biomaterials Science & Engineering as editor-in-chief. ... 2015, the new journal will feature high-quality research in ... engineered or naturally derived materials that interact with living ... as it reflects the tremendous growth in the field ...
Breaking Biology News(10 mins):Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3Deep-sea octopus has longest-known egg-brooding period 2ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2
... Molecular Biology, today publishes its Honey Bee Genome Special ... long-awaited Honey Bee Genome Sequence, published earlier this week ... Sequencing Project (HBGSP), a large scale communal project led ... National Human Genome Research Institute, is expected to usher ...
... Cancer Center at Thomas Jefferson University in Philadelphia and at ... found evidence suggesting that a mutation in a gene that ... a role in the initiation of a major form of ... Michael P. Lisanti, M.D., Ph.D., professor of cancer biology at ...
... of a cell is all about growing and dividing at ... one of the most tightly regulated cellular processes. A control ... cell cycle machinery are produced, activated and degraded to make ... work differently and are usually studied separately, but researchers at ...
Cached Biology News:Looking to a new era in bee research 2Jefferson scientists identify gene mutation potentially involved in breast cancer initiation 2Jefferson scientists identify gene mutation potentially involved in breast cancer initiation 3How nature tinkers with the cellular clock 2
(Date:7/30/2014)... , July 30, 2014 Regulus ... biopharmaceutical company leading the discovery and development of innovative ... financial results and highlights for the quarter ended June ... U.S. financial markets close. Regulus will ... 6, 2014, at 5:00 pm Eastern Daylight Time to ...
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today ... Food and Drug Administration (FDA) rare pediatric disease priority ... (BLA) submission for alirocumab.  The priority review voucher entitles ... which provides for an expedited 6-month review from the ...
(Date:7/30/2014)... W. R. Grace & Co. (NYSE: ... REVELERIS® Prep purification system , a dual-mode instrument ... researchers to perform both flash and preparative liquid ... the REVELERIS® Prep purification system, researchers can easily ... a simple touch of the screen, giving them ...
(Date:7/30/2014)... , July 30, 2014  Decision Resources ... and medical directors in the United ... of biosimilar market penetration will be the level ... (MCOs) and the expected lower cost to patients. ... biosimilars that meet their pricing expectations in order ...
Breaking Biology Technology:Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Grace Launches New REVELERIS® Prep Purification System 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3
... the American Academy ... of Dermatology, FREEPORT, N.Y., ... and its natural receptor,OCTN- 1, are a natural part of the skin,s ... in photoaged,skin. The data was presented at the Poster Session at the ...
... Feb. 11 Emisphere,Technologies, Inc. (Nasdaq: EMIS ), ... delivery of therapeutic molecules using its,eligen(R) technology, today announced ... CEO & Investor Conference on February 12, 2008 on,its ... page of the,Emisphere Web site at http://www.emisphere.com/ir.asp ...
... On Monday, January 28, The Royal,Marsden Hospital ... Modulated Arc Therapy (VMAT)* treatment in the ... the treatment, the hospital,used its existing Elekta ... control system., (Logo: http://www.newscom.com/cgi-bin/prnh/20020318/ELEKTALOGO ...
Cached Biology Technology:AGI Dermatics Clinical Data Identifies L-Ergothioneine as Part of Skin's Natural Antioxidant System 2Emisphere Technologies to Web Cast BIO CEO & Investor Conference Presentation February 12 2Elekta Announces First Volumetric Modulated Arc Therapy Cancer Treatment at Royal Marsden Hospital 2
Rab 3 Immunogen: Synthetic peptide corresponding to the N-terminal region of Rab 3 protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Mouse monoclonal [2G1] to Vancomycin ( Abpromise for all tested applications)....
Rab1A...
Biology Products: